Affordable Access

deepdyve-link
Publisher Website

Impact of time to testosterone rebound and comorbidity on the risk of cause-specific mortality in men with unfavorable-risk prostate cancer.

Authors
  • McDuff, Susan G R1, 2
  • Chen, Ming-Hui3
  • Renshaw, Andrew A4
  • Loffredo, Marian J2
  • Kantoff, Philip W5
  • D'Amico, Anthony V2
  • 1 Harvard Radiation Oncology Program, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • 2 Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • 3 Department of Statistics, University of Connecticut, Storrs, Connecticut.
  • 4 Department of Pathology, Baptist Hospital and Miami Cancer Institute, Miami, Florida.
  • 5 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Type
Published Article
Journal
Cancer
Publisher
Wiley (John Wiley & Sons)
Publication Date
Apr 01, 2018
Volume
124
Issue
7
Pages
1391–1399
Identifiers
DOI: 10.1002/cncr.31217
PMID: 29338073
Source
Medline
Keywords
License
Unknown

Abstract

The results of the current study indicate that considering an intermittent course of ADT such that the TTR approaches 18 months, instead of continuous long-term administration of ADT, in men with moderate to severe comorbidity and high-risk PC may reduce the increased risk of CVM without increasing the risk of PCSM. Cancer 2018;124:1391-9. © 2018 American Cancer Society.

Report this publication

Statistics

Seen <100 times